Premium
Remoxipride and haloperidol in schizophrenia: a double‐blind multicentre study.
Author(s) -
Ahlfors U. G.,
Rimõn R.,
Appelberg B.,
Hagert U.,
Harma P.,
Katila H.,
Mahlanen A.,
Mehtonen OP.,
Naukkarinen H.,
Outakoski J.,
Rantanen H.,
Sorri A.,
Tamminen T.,
Tolvanen E.,
Holm A.C.
Publication year - 1990
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1990.tb05298.x
Subject(s) - haloperidol , brief psychiatric rating scale , extrapyramidal symptoms , discontinuation , rating scale , clinical global impression , schizophrenia (object oriented programming) , psychology , double blind , medicine , anesthesia , psychosis , psychiatry , placebo , antipsychotic , dopamine , developmental psychology , alternative medicine , pathology
Ninety‐two patients with schizophrenia were included in a double‐blind multicentre parallel‐group trial comparing remoxipride and haloperidol. The mean daily dose during the last week of treatment was 316 mg (range, 150–600 mg) in the remoxipride group and 8.7 mg (range, 5–20 mg) in the haloperidol group. The study period was six weeks with at least one day of washout. Both Clinical Global Impression (CGI) rating, and Brief Psychiatric Rating Scale (BPRS) total scores declined at the end of the trial compared with pretreatment values in both groups. No significant differences were found between the remoxipride and haloperidol groups with regard to the treatment outcome. Treatment‐emergent extrapyramidal symptoms were statistically more frequent and more severe during haloperidol than during remoxipride treatment. Haloperidol‐treated patients reported also significantly more concentration difficulties. Severe extrapyramidal side effects in the haloperidol group and clinical ineffectiveness in the remoxipride group were the most frequent reasons for premature discontinuation of treatment.